Bookmark and Share
BioAssay: AID 434992

Late-stage luminescence-based cell-based dose response assay to identify inhibitors of NADPH oxidase 1 (NOX1): Cytotoxicity assay

Name: Late-stage luminescence-based cell-based dose response assay to identify inhibitors of NADPH oxidase 1 (NOX1): Cytotoxicity assay ..more
_
   
 Tested Compounds
 Tested Compounds
All(1)
 
 
Inactive(1)
 
 
 Tested Substances
 Tested Substances
All(1)
 
 
Inactive(1)
 
 
 Related BioAssays
 Related BioAssays
AID: 434992
Data Source: The Scripps Research Institute Molecular Screening Center (NOX1_INH_LUMI_384_3XCC50_Cytotox)
Depositor Category: NIH Molecular Libraries Probe Production Network
BioAssay Version:
Deposit Date: 2010-06-15
Hold-until Date: 2010-09-13
Modify Date: 2010-09-14

Data Table ( Complete ):           View All Data
Tested Compound:
Related Experiments
Show more
AIDNameTypeProbeComment
1792Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of NADPH oxidase 1 (Nox1): Maybridge LibraryScreening depositor-specified cross reference: Primary screen (NOX1 inhibitors)
1796Summary of probe development efforts to identify inhibitors of NADPH oxidase 1 (Nox1)Summary2 depositor-specified cross reference: Summary AID (NOX1 inhibitors)
1823Luminescence-based counterscreen for inhibitors of NADPH oxidase 1 (Nox1): biochemical high throughput screening assay to identify inhibitors of luminol (Maybridge Library)Screening depositor-specified cross reference: Counterscreen (luminal)
2532Late stage results from the probe development effort to identify inhibitors of NOX1: HEK/293 IC50Confirmatory depositor-specified cross reference: Dose response (NOX1 inhibitors, HEK/293 cells)
2538Luminescence-based cell-based dose response assay to identify inhibitors of NADPH oxidase 1 (NOX1)Confirmatory depositor-specified cross reference: Dose response screen (NOX1 inhibitors)
2539Late stage results from the probe development effort to identify inhibitors of (NADPH oxidase 1) NOX1: Family selectivityScreening depositor-specified cross reference: Counterscreen (NOX2, NOX3, NOX4 inhibitors)
2541Luminescence-based cell-based assay to identify inhibitors of NADPH oxidase 1 (NOX1)Screening depositor-specified cross reference: Confirmation screen (NOX1 inhibitors)
2545Late stage results from the probe development effort to identify inhibitors of (NADPH oxidase 1) NOX1: HEK/293 percent inhibitionScreening depositor-specified cross reference: Confirmation screen (NOX1 inhibitors, HEK/293 cells)
2556Late stage results from the probe development effort to identify inhibitors of (NADPH oxidase 1) NOX1: Xanthine OxidaseConfirmatory depositor-specified cross reference: Counterscreen (Xanthine oxidase inhibitors)
2664Late-stage luminescence-based cell-based dose response assay to identify inhibitors of NADPH oxidase 1 (NOX1): Synthesized analogsConfirmatory depositor-specified cross reference: Primary screen (NOX1 inhibitors, synthesized analogs)
2752Late-stage luminescence-based cell-based dose response assay to identify inhibitors of NADPH oxidase 1 (NOX1): Synthesized analogs 2Confirmatory depositor-specified cross reference: Primary screen (NOX1 inhibitors, synthesized analogs set 2)
2773Late-stage luminescence-based cell-based dose response assay to identify inhibitors of NADPH oxidase 1 (NOX1): Synthesized analogs 3Confirmatory depositor-specified cross reference: Primary screen (NOX1 inhibitors, synthesized analogs set 3)
2808Late-stage luminescence-based cell-based dose response assay to identify inhibitors of NADPH oxidase 1 (NOX1): Purchased analogsConfirmatory depositor-specified cross reference: Primary screen (NOX1 inhibitors, purchased analogs)
2819Late-stage luminescence-based cell-based dose response assay to identify inhibitors of NADPH oxidase 1 (NOX1): Purchased analogs 2Confirmatory depositor-specified cross reference: Primary screen (NOX1 inhibitors, purchased analogs set 2)
434953Late-stage radioligand binding dose response assay to identify inhibitors of NADPH oxidase 1 (NOX1): PDSP screen KiScreening depositor-specified cross reference: Psychoactive Drug Screening Program secondary screen (NOX1 inhibitors)
434974Late-stage radioligand binding assay to identify inhibitors of NADPH oxidase 1 (NOX1): PDSP screenScreening depositor-specified cross reference: Psychoactive Drug Screening Program primary screen (NOX1 inhibitors)
463255Late-stage luminescence-based cell-based dose response assay to identify inhibitors of NADPH oxidase 1 (NOX1): Cytotoxicity assay 2Confirmatory depositor-specified cross reference
488778Late-stage microscopic assay to identify inhibitors of NADPH oxidase 1 (NOX1): Inhibition of extracellular matrix degradationOther depositor-specified cross reference
504381Late-stage radioligand binding assay to identify inhibitors of NADPH oxidase 1 (NOX1): PDSP screen Set 2Other depositor-specified cross reference
504410Late-stage radioligand binding dose response assay to identify inhibitors of NADPH oxidase 1 (NOX1): PDSP screen Ki Set 2Confirmatory depositor-specified cross reference
2154Late stage results from the probe development effort to identify inhibitors of Nox1.Screening same project related to Summary assay
434993Late-stage microscopic assay to identify inhibitors of NADPH oxidase 1 (NOX1): Inhibition of invadopodia formationOther same project related to Summary assay
434997Luminescence-based cell-based dose response assay to identify inhibitors of NADPH oxidase 1 (NOX1): Cherry picks 2Confirmatory same project related to Summary assay
435002Late stage results from the probe development effort to identify inhibitors of NOX1: HEK/293 IC50 Set 2Confirmatory same project related to Summary assay
435009Late stage results from the probe development effort to identify inhibitors of (NADPH oxidase 1) NOX1: Xanthine Oxidase Set 2Confirmatory same project related to Summary assay
435013Late stage results from the probe development effort to identify inhibitors of (NADPH oxidase 1) NOX1: Family selectivity: Set 2Confirmatory same project related to Summary assay
Description:
Data Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)
Center Affiliation: The Scripps Research Institute, TSRI
Assay Provider: Gary Bokoch, TSRI
Network: Molecular Libraries Probe Production Center Network (MLPCN)
Grant Proposal Number: 1 R03 MH083264-01A1
Grant Proposal PI: Gary Bokoch, TSRI
External Assay ID: NOX1_INH_LUMI_384_3XCC50_Cytotox

Name: Late-stage luminescence-based cell-based dose response assay to identify inhibitors of NADPH oxidase 1 (NOX1): Cytotoxicity assay

Description:

Host defense mechanisms are diverse and include receptor-initiated signaling pathways, antibody and cytokine production, and the generation of reactive oxygen species (ROS) such as hydroxyl radical and hypochlorus acid to kill microorganisms (1). In activated phagocytic cells, the membrane integrated protein gp91phox serves as the catalytic cytochrome b subunit of the respiratory burst oxidase used to generate superoxide in an NADPH-dependent manner for host defense (2). Generation of ROS has also been identified in non-phagocytic cells (3). One important enzyme involved in ROS production in non-leukocyte tissues is NADPH oxidase 1 (NOX1), a homolog of gp91phox. NOX1 is highly expressed in colon epithelial cells where it can generate ROS to interact with normal and pathogenic bacteria (3-5). However, excess ROS production is associated with damage to the intestinal mucosa, particularly in mucosal lesions of inflammatory bowel disease (IBD) (4). Studies showing that NOX1 levels are increased in human prostate cancer (6) and that cells overexpressing NOX1 have a transformed appearance, exhibit anchorage-independent growth, and induce vascularized tumor formation in athymic mice (3, 7), suggest that NOX1 may also play a role in angiogenesis, cell growth, and tumor pathogenesis (8, 9). The identification of inhibitors of NOX1 may lead to potential candidates for excess cell proliferation, cancer, and IBD.

References:

1. Takeya, R. and Sumimoto, H., Molecular mechanism for activation of superoxide-producing NADPH oxidases. Mol Cells, 2003. 16(3): p. 271-7.
2. Cheng, G., Cao, Z., Xu, X., van Meir, E.G., and Lambeth, J.D., Homologs of gp91phox: cloning and tissue expression of Nox3, Nox4, and Nox5. Gene, 2001. 269(1-2): p. 131-40.
3. Suh, Y.A., Arnold, R.S., Lassegue, B., Shi, J., Xu, X., Sorescu, D., Chung, A.B., Griendling, K.K., and Lambeth, J.D., Cell transformation by the superoxide-generating oxidase Mox1. Nature, 1999. 401(6748): p. 79-82.
4. Szanto, I., Rubbia-Brandt, L., Kiss, P., Steger, K., Banfi, B., Kovari, E., Herrmann, F., Hadengue, A., and Krause, K.H., Expression of NOX1, a superoxide-generating NADPH oxidase, in colon cancer and inflammatory bowel disease. J Pathol, 2005. 207(2): p. 164-76.
5. Rokutan, K., Kawahara, T., Kuwano, Y., Tominaga, K., Nishida, K., and Teshima-Kondo, S., Nox enzymes and oxidative stress in the immunopathology of the gastrointestinal tract. Semin Immunopathol, 2008. 30(3): p. 315-27.
6. Lim, S.D., Sun, C., Lambeth, J.D., Marshall, F., Amin, M., Chung, L., Petros, J.A., and Arnold, R.S., Increased Nox1 and hydrogen peroxide in prostate cancer. Prostate, 2005. 62(2): p. 200-7.
7. Arnold, R.S., Shi, J., Murad, E., Whalen, A.M., Sun, C.Q., Polavarapu, R., Parthasarathy, S., Petros, J.A., and Lambeth, J.D., Hydrogen peroxide mediates the cell growth and transformation caused by the mitogenic oxidase Nox1. Proc Natl Acad Sci U S A, 2001. 98(10): p. 5550-5.
8. Ushio-Fukai, M. and Nakamura, Y., Reactive oxygen species and angiogenesis: NADPH oxidase as target for cancer therapy. Cancer Lett, 2008. 266(1): p. 37-52.
9. Kobayashi, S., Nojima, Y., Shibuya, M., and Maru, Y., Nox1 regulates apoptosis and potentially stimulates branching morphogenesis in sinusoidal endothelial cells. Exp Cell Res, 2004. 300(2): p. 455-62.

Keywords:

NOX1, NADPH oxidase 1, cancer, inflammation, 384, inhibitor, inhibition, late stage, dose response, HT29, ROS, luciferase, luminescence, CellTiter Glo, cell viability, cytotoxicity, Scripps, The Scripps Research Institute Molecular Screening Center, SRIMSC, Molecular Libraries Probe Production Center Network, MLPCN.
Protocol
Assay Overview:

The purpose of this assay is to eliminate cytotoxic compounds that would behave as false positives in the primary screening assay for inhibitors of NADPH oxidase 1 (NOX1). In this assay, HT29 cells are incubated with test compounds, followed by determination of cell viability. The assay utilizes the CellTiter-Glo luminescent reagent to measure intracellular ATP in viable cells. Luciferase present in the reagent catalyzes the oxidation of beetle luciferin to oxyluciferin and light in the presence of cellular ATP. Well luminescence is directly proportional to ATP levels and cell viability. As designed, compounds that reduce cell viability will reduce ATP levels, luciferin oxidation and light production, resulting in decreased well luminescence. Compounds were tested in triplicate in a 10-point 1:3 dilution series starting at a nominal test concentration of 40 uM.

Protocol Summary:

Prior to the start of the assay 5X 104 HT29 cells in a 20 uL volume of HBSS were dispensed into each well of 384-well tissue culture-treated microtiter plates. The assay was started immediately by dispensing 50 nL of test compound in DMSO, DMSO alone, or rotenone as a positive control (150 uM final concentration) to the appropriate wells. The plates were then incubated for 1 hour at 37 degrees C. The assay was stopped by dispensing 20 uL of CellTiter-Glo reagent to each well, followed by incubation at room temperature for 15 minutes. Well luminescence was measured on the ViewLux plate reader.

Compounds were considered to be toxic (active) when well luminescence was decreased > 25% compared to vehicle wells (vehicle and rotenone wells were set to 0% and 100% respectively), and nontoxic (inactive) when well luminescence was decreased ≤ 25% compared to vehicle wells.

PubChem Activity Outcome and Score:

The PubChem Activity Score range for inactive compounds is 0-0. There are no active compounds.

List of Reagents:

HT29 cells (provided by Assay Provider)
DMEM medium (GIBCO, part 25200)
Hank's Balanced Salt Solution (Invitrogen, part 14025-092)
100X Penicillin-Streptomycin mix (Invitrogen, part 15140)
Trypsin-EDTA solution (Invitrogen, part 25200-056)
Fetal Bovine Serum (Invitrogen, part 16140-071)
Rotenone (Sigma R8875)
CellTiter Glo (Promega, part S-G7570)
DMSO (Sigma 472301)
150 mm tissue culture dishes (Corning, part 430599)
384-well plates (Corning, 3704)
Comment
Possible artifacts of this assay can include, but are not limited to: dust or lint located in or on wells of the microtiter plate, compounds that non-specifically modulate luciferase activity, and compounds that quench or emit luminescence within the well.
Categorized Comment - additional comments and annotations
From PubChem:
Assay Format: Cell-based
Assay Type: Toxicity
Assay Cell Type: HT-29
Result Definitions
Show more
TIDNameDescriptionHistogramTypeUnit
OutcomeThe BioAssay activity outcomeOutcome
1Inhibition at 40 uM [1] (40μM**)Value of % Inhibition at 40 uM inhibitor concentration; replicate one.Float%
2Inhibition at 40 uM [2] (40μM**)Value of % Inhibition at 40 uM inhibitor concentration; replicate two.Float%
3Inhibition at 40 uM [3] (40μM**)Value of % Inhibition at 40 uM inhibitor concentration; replicate three.Float%
4Inhibition at 13.33 uM [1] (13.33μM**)Value of % Inhibition at 13.33 uM inhibitor concentration; replicate one.Float%
5Inhibition at 13.33 uM [2] (13.33μM**)Value of % Inhibition at 13.33 uM inhibitor concentration; replicate two.Float%
6Inhibition at 13.33 uM [3] (13.33μM**)Value of % Inhibition at 13.33 uM inhibitor concentration; replicate three.Float%
7Inhibition at 4.44 uM [1] (4.44μM**)Value of % Inhibition at 4.44 uM inhibitor concentration; replicate one.Float%
8Inhibition at 4.44 uM [2] (4.44μM**)Value of % Inhibition at 4.44 uM inhibitor concentration; replicate two.Float%
9Inhibition at 4.44 uM [3] (4.44μM**)Value of % Inhibition at 4.44 uM inhibitor concentration; replicate three.Float%
10Inhibition at 1.48 uM [1] (1.48μM**)Value of % Inhibition at 1.48 uM inhibitor concentration; replicate one.Float%
11Inhibition at 1.48 uM [2] (1.48μM**)Value of % Inhibition at 1.48 uM inhibitor concentration; replicate two.Float%
12Inhibition at 1.48 uM [3] (1.48μM**)Value of % Inhibition at 1.48 uM inhibitor concentration; replicate three.Float%
13Inhibition at 0.494 uM [1] (0.494μM**)Value of % Inhibition at 0.494 uM inhibitor concentration; replicate one.Float%
14Inhibition at 0.494 uM [2] (0.494μM**)Value of % Inhibition at 0.494 uM inhibitor concentration; replicate two.Float%
15Inhibition at 0.494 uM [3] (0.494μM**)Value of % Inhibition at 0.494 uM inhibitor concentration; replicate three.Float%
16Inhibition at 0.165 uM [1] (0.165μM**)Value of % Inhibition at 0.165 uM inhibitor concentration; replicate one.Float%
17Inhibition at 0.165 uM [2] (0.165μM**)Value of % Inhibition at 0.165 uM inhibitor concentration; replicate two.Float%
18Inhibition at 0.165 uM [3] (0.165μM**)Value of % Inhibition at 0.165 uM inhibitor concentration; replicate three.Float%
19Inhibition at 0.055 uM [1] (0.055μM**)Value of % Inhibition at 0.055 uM inhibitor concentration; replicate one.Float%
20Inhibition at 0.055 uM [2] (0.055μM**)Value of % Inhibition at 0.055 uM inhibitor concentration; replicate two.Float%
21Inhibition at 0.055 uM [3] (0.055μM**)Value of % Inhibition at 0.055 uM inhibitor concentration; replicate three.Float%
22Inhibition at 0.018 uM [1] (0.018μM**)Value of % Inhibition at 0.018 uM inhibitor concentration; replicate one.Float%
23Inhibition at 0.018 uM [2] (0.018μM**)Value of % Inhibition at 0.018 uM inhibitor concentration; replicate two.Float%
24Inhibition at 0.018 uM [3] (0.018μM**)Value of % Inhibition at 0.018 uM inhibitor concentration; replicate three.Float%
25Inhibition at 0.006 uM [1] (0.006μM**)Value of % Inhibition at 0.006 uM inhibitor concentration; replicate one.Float%
26Inhibition at 0.006 uM [2] (0.006μM**)Value of % Inhibition at 0.006 uM inhibitor concentration; replicate two.Float%
27Inhibition at 0.006 uM [3] (0.006μM**)Value of % Inhibition at 0.006 uM inhibitor concentration; replicate three.Float%
28Inhibition at 0.002 uM [1] (0.002μM**)Value of % Inhibition at 0.002 uM inhibitor concentration; replicate one.Float%
29Inhibition at 0.002 uM [2] (0.002μM**)Value of % Inhibition at 0.002 uM inhibitor concentration; replicate two.Float%
30Inhibition at 0.002 uM [3] (0.002μM**)Value of % Inhibition at 0.002 uM inhibitor concentration; replicate three.Float%

** Test Concentration.
Additional Information
Grant Number: 1 R03 MH083264-01A1

Data Table (Concise)
Data Table ( Complete ):     View All Data
PageFrom: